Olutasidenib Patent Expiration
Olutasidenib is Used for treating acute myeloid leukemia with IDH1 mutation in adult patients. It was first introduced by Rigel Pharmaceuticals Inc
Olutasidenib Patents
Given below is the list of patents protecting Olutasidenib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rezlidhia | US11723905 | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile | Nov 12, 2039 | Rigel Pharms |
| Rezlidhia | US11738018 | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) | Jul 17, 2039 | Rigel Pharms |
| Rezlidhia | US10532047 | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile | May 16, 2039 | Rigel Pharms |
| Rezlidhia | US10959994 | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile | May 16, 2039 | Rigel Pharms |
| Rezlidhia | US11013733 | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) | May 16, 2039 | Rigel Pharms |
| Rezlidhia | US11013734 | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation | May 16, 2039 | Rigel Pharms |
| Rezlidhia | US11376246 | Inhibiting mutant IDH-1 | May 16, 2039 | Rigel Pharms |
| Rezlidhia | US11497743 | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation | May 16, 2039 | Rigel Pharms |
| Rezlidhia | US12053463 | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile | May 16, 2039 | Rigel Pharms |
| Rezlidhia | US10414752 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | Sep 18, 2035 | Rigel Pharms |
| Rezlidhia | US10550098 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | Sep 18, 2035 | Rigel Pharms |
| Rezlidhia | US11498913 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | Sep 18, 2035 | Rigel Pharms |
| Rezlidhia | US9834539 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | Sep 18, 2035 | Rigel Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Olutasidenib's patents.
Latest Legal Activities on Olutasidenib's Patents
Given below is the list recent legal activities going on the following patents of Olutasidenib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Feb, 2024 | US11013734 |
| Email Notification Critical | 28 Feb, 2024 | US10959994 |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Feb, 2024 | US10550098 |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Feb, 2024 | US10959994 |
| Email Notification Critical | 28 Feb, 2024 | US10414752 |
| Email Notification Critical | 28 Feb, 2024 | US10550098 |
| Email Notification Critical | 28 Feb, 2024 | US10532047 |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Feb, 2024 | US10414752 |
| Change in Power of Attorney (May Include Associate POA) Critical | 28 Feb, 2024 | US10532047 |
| Email Notification Critical | 28 Feb, 2024 | US11013734 |
Olutasidenib's Family Patents
